We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $214M
1-Year Est. Return 185.33%
This Fund
S&P 500
This Quarter Est. Return
+47.89%
1 Year Est. Return
+185.33%
3 Year Est. Return
+327.48%
5 Year Est. Return
+458.62%
10 Year Est. Return
+1,549.55%
AUM
$214M
AUM Growth
+$38.2M
Cap. Flow
-$12.5M
Cap. Flow %
-5.84%
Top 10 Hldgs %
59.94%
Holding
87
New
14
Increased
17
Reduced
22
Closed
15

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$3.66M
2
VIR icon
Vir Biotechnology
VIR
+$2.09M
3
ABVX
Abivax
ABVX
+$1.92M
4
HALO icon
Halozyme
HALO
+$1.58M
5
BIOA
BioAge Labs
BIOA
+$1.25M

Top Sells

Rank Stock Value
1
KLAC icon
KLA
KLAC
+$4.04M
2
CMPS
Compass Pathways
CMPS
+$3.5M
3
GPCR icon
Structure Therapeutics
GPCR
+$3.36M
4
OCUL icon
Ocular Therapeutix
OCUL
+$2.71M
5
NVCR icon
NovoCure
NVCR
+$2.21M

Sector Composition

Rank Sector Weight
1 Healthcare 63.39%
2 Technology 32.27%
3 Energy 3.51%
4 Materials 0.53%
5 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PACB icon
26
Pacific Biosciences
PACB
$404M
$2.27M 1.06%
1,350,000
-150,000
-10% -$218K
ABVX
27
Abivax
ABVX
$9.95B
$2.27M 1.06%
+17,000
New +$1.92M
VIR icon
28
Vir Biotechnology
VIR
$1.94B
$2.24M 1.05%
+220,000
New +$2.09M
BIIB icon
29
Biogen
BIIB
$33.2B
$1.94M 0.91%
9,000
+4,000
+80% +$765K
EQT icon
30
EQT Corp
EQT
$34.8B
$1.84M 0.86%
34,619
– –
BIOA
31
BioAge Labs
BIOA
$436M
$1.69M 0.79%
+69,000
New +$1.25M
TVTX icon
32
Travere Therapeutics
TVTX
$6.27B
$1.65M 0.77%
29,000
-200
-0.7% -$8.87K
QDEL icon
33
QuidelOrtho
QDEL
$955M
$1.57M 0.73%
89,377
+6,829
+8% +$90.2K
AXSM icon
34
Axsome Therapeutics
AXSM
$10.9B
$1.47M 0.69%
6,000
– –
FHTX icon
35
Foghorn Therapeutics
FHTX
$289M
$1.38M 0.64%
281,937
+207
+0.1% +$919
BCYC
36
Bicycle Therapeutics
BCYC
$297M
$1.33M 0.62%
313,616
-149,983
-32% -$688K
GPCR icon
37
Structure Therapeutics
GPCR
$3.38B
$1.29M 0.6%
24,000
-76,000
-76% -$3.36M
XENE icon
38
Xenon Pharmaceuticals
XENE
$5.85B
$1.27M 0.59%
21,032
+32
+0.2% +$1.78K
NVO
39
Novo Nordisk
NVO
$210B
$1.15M 0.54%
+24,000
New +$1.03M
FCX icon
40
Freeport-McMoran
FCX
$104B
$1.13M 0.53%
18,035
-5
-0% -$321
IMNM icon
41
Immunome
IMNM
$3.08B
$1.06M 0.5%
50,000
– –
PHVS icon
42
Pharvaris
PHVS
$2.5B
$1.03M 0.48%
29,847
– –
HROW icon
43
Harrow
HROW
$1.43B
$1.02M 0.48%
24,000
– –
ADAG
44
Adagene
ADAG
$248M
$1.01M 0.47%
+240,000
New +$903K
DFTX
45
Definium Therapeutics
DFTX
$5.11B
$941K 0.44%
+20,000
New +$494K
SLN
46
Silence Therapeutics
SLN
$919M
$782K 0.37%
+71,218
New +$501K
BBIO icon
47
BridgeBio Pharma
BBIO
$14.7B
$651K 0.3%
8,741
+53
+0.6% +$3.71K
FDMT icon
48
4D Molecular Therapeutics
FDMT
$812M
$645K 0.3%
+48,505
New +$473K
URGN icon
49
UroGen Pharma
URGN
$2.19B
$607K 0.28%
+16,487
New +$447K
PHAT icon
50
Phathom Pharmaceuticals
PHAT
$732M
$597K 0.28%
55,000
-140,000
-72% -$1.6M
1
2
3 4

Similar funds

EFIC
Eliot Finkel Investment Counsel Beverly Hills, California $214M AUM 62.72% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
TCM
Tassel Capital Management Matthews, North Carolina $214M AUM 16.99% 1-Year Est. Return
EFS
Econ Financial Services Harrisburg, Pennsylvania $214M AUM 10.53% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return
KWM
Kingsman Wealth Management Pensacola, Florida $214M AUM 46.9% 1-Year Est. Return
FA
Fortis Advisors Wayne, Pennsylvania $214M AUM 41.3% 1-Year Est. Return
MSWM
Mader & Shannon Wealth Management Kansas City, Missouri $214M AUM 23.75% 1-Year Est. Return

Birchview Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Birchview Capital held 87 positions worth $214M, up 22% from $176M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Birchview Capital withdrew a net $12.5M in Q2 2026, closing 15 positions and reducing 22 holdings. Its most notable exit was NovoCure, an estimated $2.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 73% a quarter earlier, followed by Technology and Energy.

Against the trend, Birchview Capital opened a new position in Vir Biotechnology worth $2.24M.

  • Birchview Capital's largest Q2 2026 buy was Vir Biotechnology: 220,000 shares worth $2.24M.
  • Birchview Capital added most to Nektar Therapeutics in Q2 2026, an estimated $3.66M increase.
  • Birchview Capital's biggest Q2 2026 reduction was KLA, cutting an estimated $4.04M.
  • Birchview Capital fully exited NovoCure in Q2 2026, selling an estimated $2.21M.
  • Birchview Capital's ten largest holdings make up 60% of its $214M portfolio in Q2 2026.
  • Birchview Capital opened 14 new positions and closed 15 in Q2 2026.
  • Birchview Capital's portfolio value rose 22% quarter-over-quarter to $214M.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.